Yes, an NAD-targeting product can cause harm, but “NAD+” is not one exposure. Oral NMN and oral nicotinamide riboside, or NR, have relatively reassuring short-term human safety data at studied doses. IV NAD+ has limited safety data and can cause marked symptoms during infusion. Nicotinic acid, often called niacin, has a separate and well-established adverse-effect profile.[1][2][3][4]
None of those findings establish long-term safety for every dose, formulation, route or population. The first safety question is therefore simple: what molecule are you actually taking, and how is it being administered?
First identify what “NAD+” means on the product
NAD+ is a molecule used throughout human metabolism. If you want the biology first, see our guide to what NAD+ is.
A product marketed around NAD+ may contain direct NAD+, NMN, NR, nicotinic acid, nicotinamide or a multi-ingredient blend. It may be swallowed, injected or infused. Those are different exposures, so their safety evidence cannot be merged.
This distinction also matters when comparing NAD+ supplements. A safety finding for oral NMN does not prove that IV NAD+ has the same adverse-event profile. A flushing reaction to nicotinic acid does not automatically belong on an NR or NMN side-effect list.
CELLSHE EVIDENCE MAP
NAD-targeting safety by molecule and route
| Exposure | What human evidence supports | What remains unresolved | Evidence level for this safety question |
|---|---|---|---|
| Oral NMN | Randomized trials and a 2026 meta-analysis did not show a clear increase in overall adverse events, serious adverse events, withdrawals, gastrointestinal events or liver enzymes during short-term use. | Rare harms, multi-year use, some higher-risk populations and long-term cancer outcomes have not been established. | Human randomized evidence |
| Oral NR | Several randomized trials found similar adverse-event patterns to placebo across studied doses and durations. Trials include 1,000 mg/day for 6 to 8 weeks and 2,000 mg/day for 12 weeks. | Long-term safety remains less certain. Very high-dose data come from small clinical populations and should not be generalized to healthy adults. | Human randomized evidence |
| Direct oral NAD+ | Human intervention evidence exists, but direct oral NAD+ is far less characterized than oral NMN or NR in the modern wellness literature. | Its safety profile cannot be inferred from precursor trials. Formulation and absorption also matter. | Sparse human evidence |
| IV NAD+ | A small 2019 slow-infusion pilot reported no adverse events during a 6-hour infusion. A 2026 retrospective commercial study reported gastrointestinal symptoms, increased heart rate and chest pressure during 500 mg infusions. | There is no large randomized safety program defining rates by dose or infusion protocol. Long-term safety is unknown. | Limited human evidence |
| Nicotinic acid (niacin) | Flushing is a well-established dose-related effect. High therapeutic doses can also affect blood pressure, glucose, uric acid and liver function. | This safety profile should not be copied onto NMN, NR or direct NAD+ as if the compounds were interchangeable. | Established human evidence |
Sources: Yang et al. 2026 [1]; Bhasin et al. 2023 [2]; Gallagher and Emmanuel 2026 [3]; NIH Office of Dietary Supplements [4]; Martens et al. 2018 [9]; Conze et al. 2019 [10]; Dollerup et al. 2018 [11]; Grant et al. 2019 [14]; Reyna et al. 2026 [15].
CELLSHE interpretation: the most important safety distinction is the exact molecule plus the route. Evidence from one row should not be used as proof for another.
NMN: short-term trial data are reassuring, not permanent clearance
The strongest current NMN safety summary is a 2026 systematic review and meta-analysis. It included 15 randomized trials, with 10 trials and 383 participants contributing extractable safety data. Doses ranged from 250 to 2,000 mg per day and study durations ranged from 14 days to 24 weeks.[1]
The pooled analysis found no significant increase in total adverse events, serious adverse events, withdrawals due to adverse events, gastrointestinal events, nervous-system events, skin or allergic events, ALT or AST.[1]
That is stronger evidence than a generic list claiming NMN commonly causes nausea, headache or flushing. Existing randomized trials do not support presenting those symptoms as a consistent NMN adverse-event pattern.
Individual trials add useful exposure data. In 31 healthy adults, 1,250 mg of beta-NMN daily for four weeks produced no severe adverse events or changes beyond expected physiological variation in the measured clinical tests.[5] A 60-day trial in 80 healthy middle-aged adults tested 300, 600 and 900 mg per day and reported no safety issue based on adverse events and clinical laboratory monitoring.[6]
An earlier single-dose study in 10 healthy men tested 100, 250 and 500 mg of NMN and found no significant clinical symptoms or harmful changes during short-term monitoring.[19]
Other randomized studies have tested 250 mg per day for 12 weeks in healthy older men and in older Japanese adults, adding short-term safety exposure in different populations.[7][8]
A research dose is not a personal dose recommendation. The current NMN data support a statement about short-term tolerability under studied conditions. They do not establish that any dose is optimal, necessary or safe for indefinite use.
A 2026 European Food Safety Authority assessment also concluded that a highly pure beta-NMN novel-food preparation was safe under its proposed conditions of use at up to 300 mg per day for adults, excluding pregnant and lactating women. That conclusion applies to the assessed ingredient specifications and proposed use, not to every NMN product or dose on the market.[20]
NR: several human trials support short-term tolerability
Nicotinamide riboside has a longer modern human trial record than direct NAD+.
In a randomized crossover trial, 30 healthy middle-aged and older adults were assigned to NR or placebo. Twenty-four completed the trial. At the tested dose, adverse events were mild, no serious adverse events occurred, and no participant withdrew during the NR phase because of side effects.[9]
An 8-week randomized trial in 140 overweight but otherwise healthy adults compared placebo with 100, 300 or 1,000 mg of NR chloride per day. Adverse-event incidence and severity were similar across groups, and the study reported no flushing or serious adverse events.[10] The study was funded by ChromaDex, and two authors were affiliated with the company, so it should be read alongside independent trials rather than alone.
A separate randomized trial gave 40 obese, insulin-resistant men 2,000 mg of NR per day or placebo for 12 weeks. No serious adverse events due to NR were reported, and safety blood tests remained normal.[11]
High-dose exposure has also been studied in disease populations. A small phase I trial in 20 people with Parkinson's disease tested 3,000 mg of NR per day for four weeks. It found no treatment-associated moderate or severe adverse events, but the dose, population and short duration make it poor evidence for routine high-dose use in healthy adults.[12]
A 2025 Nature Metabolism review reached the broader conclusion that human NAD+ precursor studies remain limited in duration and clinical scope, even as biomarker effects are increasingly well characterized.[13]
Direct NAD+ cannot borrow the precursor safety record
This is the central correction to the previous version of this page.
NMN and NR are precursors used by the body in NAD-related metabolism. They are not direct NAD+. A trial of oral NMN cannot establish the safety of direct oral NAD+, and neither can establish the safety of an infusion.
What about direct oral NAD+?
Direct oral NAD+ has a thinner modern human evidence base than NMN or NR. Reviews of NAD-targeting interventions find that most contemporary oral human trials involve precursors such as NR and NMN rather than the parent NAD+ molecule.[2][3]
That does not prove direct oral NAD+ is harmful. It means the evidence is too sparse to assign it the same safety confidence as better-studied oral precursors.
What are the side effects of IV NAD+?
The direct IV evidence is limited and protocol-sensitive.
A 2019 pilot study infused 750 mg of NAD+ over six hours in healthy men while tracking NAD-related metabolites. The investigators reported no adverse events during the six-hour infusion. This was a small pharmacokinetic pilot, not a large safety trial.[14]
A 2026 retrospective study from a commercial wellness setting looked at four consecutive days of 500 mg IV NAD+ or IV NR with 30-day follow-up. People receiving IV NAD+ reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusion. The symptoms resolved when the infusion ended, and average NAD+ infusion time was about 97 minutes.[15]
The same study found no significant changes in ALT, AST, hsCRP, BUN-to-creatinine ratio or TSH over follow-up. Seven authors were employees of the commercial wellness company whose client records supplied the data.[15]
These two studies should not be forced into one universal side-effect rate. They used different protocols and study designs. Together, they show why infusion speed, setting and route cannot be ignored.
For the route question in more depth, see our comparison of NAD+ IV versus oral approaches.
Flushing belongs to nicotinic acid, not to “NAD+” as a category
Nicotinic acid is a form of niacin, or vitamin B3. It can feed into NAD metabolism, but its adverse-effect profile is its own.
The NIH Office of Dietary Supplements states that nicotinic acid at supplemental doses can cause skin flushing, burning, tingling and itching. The adult tolerable upper intake level for supplemental niacin is 35 mg per day, based on flushing risk in the general population. That limit does not apply to medically supervised therapeutic niacin.[4]
At high therapeutic doses, nicotinic acid can also cause low blood pressure, fatigue, impaired glucose tolerance, elevated uric acid and liver toxicity. Nicotinamide has a different profile and does not usually produce the same flushing reaction.[4]
The 35 mg niacin limit is not an NMN or NR dose limit. It should not be copied across chemically different NAD-related products.
Does raising NAD+ increase cancer risk?
Human supplement trials have not established that NMN, NR or direct NAD+ increases cancer incidence. They also have not run long enough, or been designed, to rule out an effect on long-term cancer risk.
The biological concern is plausible because NAD metabolism participates in DNA repair, cellular energetics and signaling. Cancer cells also use these systems. That makes the relationship context-dependent rather than a simple “more NAD+ is good” or “more NAD+ feeds cancer” rule.[2]
A frequently cited 2023 study involved a triple-negative breast cancer mouse model. NR supplementation increased tumor prevalence and brain metastases in that preclinical model.[16]
That is a real preclinical safety signal. It is not evidence that NR causes cancer in people.
For someone with active cancer or receiving cancer treatment, the evidence gap matters more because treatment decisions depend on tumor type, therapy and clinical context. NAD-raising supplements should be discussed with the oncology team rather than treated as a generic wellness decision.
When should the safety bar be higher?
A molecule-specific evidence map still cannot account for every person's medical context. A higher level of review is reasonable in several situations.
- Active cancer or cancer treatment: long-term human cancer-risk data for NAD-raising supplements are inadequate, and oncology treatment context matters.
- Pregnancy or breastfeeding: wellness-use data for NMN, NR and direct NAD+ are not adequate to establish safety across pregnancy or lactation. The 2026 EFSA NMN assessment excluded pregnant and lactating women from its target population.[20]
- Prescription medicines or planned surgery: FDA advises discussing dietary supplements with a clinician or pharmacist because supplements can interact with medicines and may matter around procedures.[18]
- High-dose nicotinic acid use: known effects on liver function, glucose, uric acid and blood pressure make this a different safety problem from typical NR or NMN trials.[4]
- IV NAD+: the direct evidence base is small, the route bypasses the gastrointestinal tract, and infusion-related symptoms have been reported.[14][15]
This is not evidence that every person in these groups will have a problem. It is a reason not to treat short trials in generally healthy adults as universal clearance.
A better way to judge an NAD+ safety claim
Before accepting “clinically studied” or “well tolerated” on a product page, check whether the study actually matches the product.
- Name the molecule. Direct NAD+, NMN, NR and nicotinic acid are not interchangeable.
- Name the route. Oral, IV and injected evidence must stay separate.
- Check the studied dose and duration. A four-week safety study does not establish multi-year safety.
- Check the population. Healthy adults, older adults and people with a disease do not answer the same safety question.
- Check the whole formula. A multi-ingredient product can add safety questions not answered by a study of one ingredient.
FDA does not approve dietary supplements for safety and effectiveness before they are sold. Manufacturers and distributors carry the initial responsibility for meeting supplement safety and labeling requirements.[17]
So, can NAD+ be harmful?
Yes. NAD-targeting products can cause adverse effects, and their unknowns are not the same.
Short-term human evidence for oral NMN and NR is reasonably reassuring under studied conditions. Direct oral NAD+ is less characterized. IV NAD+ has a thinner evidence base and can produce substantial transient infusion symptoms. Nicotinic acid has known dose-related adverse effects that should not be generalized to other NAD-related molecules.
The cancer question remains unresolved in humans over the long term. Preclinical findings deserve attention, but they should stay labeled as preclinical.
The defensible safety question is therefore not only “Is NAD+ safe?” It is: which molecule, at what dose, by which route, for how long, and in whom?
References
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. PMID: 42514320. PubMed.
- Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr Rev. 2023;44(6):1047-1073. PMID: 37364580. PubMed.
- Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PMID: 41655607. PubMed.
- NIH Office of Dietary Supplements. Niacin: Fact Sheet for Health Professionals. NIH ODS.
- Fukamizu Y, Uchida Y, Shiozawa M, et al. Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12:14442. PMID: 36002548. PubMed.
- Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. PMID: 36482258. PubMed.
- Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5. PMID: 35927255. PubMed.
- Kim M, Seol J, Sato T, et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022;14(4):755. PMID: 35215405. PubMed.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PMID: 29599478. PubMed.
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9:9772. PMID: 31278280. PubMed.
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PMID: 29992272. PubMed.
- Brakedal B, Dölle C, Riemer F, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023;14:7793. PMID: 38016950. PubMed.
- Vinten KT, Trętowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab. 2025;7(10):1974-1990. PMID: 41083806. PubMed.
- Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257. PMID: 31572171. PubMed.
- Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID: 41704678. PubMed.
- Maric T, Bazhin A, Khodakivskyi P, et al. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism. Biosens Bioelectron. 2023;220:114826. PMID: 36371959. PubMed.
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. FDA.
- U.S. Food and Drug Administration. Mixing Medications and Dietary Supplements Can Endanger Your Health. FDA.
- Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. PMID: 31685720. PubMed.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of beta-nicotinamide mononucleotide pursuant to Regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source. EFSA J. 2026;24(5):e10007. PMID: 42125559. PubMed.
Editorial note: This article separates safety evidence by molecule, route, dose, duration and study population. Human precursor trials are not used as proof of direct NAD+ safety, and preclinical cancer findings are not presented as human outcomes.
